Anna Reva

Anna Reva

Auto-generated profile, based on publicly available information

Anna Reva

Icahn School of Medicine, Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Cancer Discovery
Verified
Journal Article
Closed access
RARahat Alam
Rahat Alam
ARAnna Reva
Anna Reva
DEDavid G. Edwards
David G. Edwards
BLBree M. Lege
Bree M. Lege
LMLaura S. Munoz-Arcos
Laura S. Munoz-Arcos
IBIgor L. Bado
Igor L. Bado
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.

2 April 2025
Verified
Other
Open access
RARahat Alam
Rahat Alam
ARAnna Reva
Anna Reva
DEDavid G. Edwards
David G. Edwards
BLBree M. Lege
Bree M. Lege
LMLaura S. Munoz-Arcos
Laura S. Munoz-Arcos
IBIgor L. Bado
Igor L. Bado
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer.Significance:Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.

17 June 2026
Verified
Other
Open access
PDF file
RARahat Alam
Rahat Alam
ARAnna Reva
Anna Reva
DEDavid G. Edwards
David G. Edwards
BLBree M. Lege
Bree M. Lege
LMLaura S. Munoz-Arcos
Laura S. Munoz-Arcos
IBIgor L. Bado
Igor L. Bado
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.

2 April 2025
Verified
Other
Open access
PDF file
RARahat Alam
Rahat Alam
ARAnna Reva
Anna Reva
DEDavid G. Edwards
David G. Edwards
BLBree M. Lege
Bree M. Lege
LMLaura S. Munoz-Arcos
Laura S. Munoz-Arcos
IBIgor L. Bado
Igor L. Bado
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.